METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Feature|Articles|August 19, 2026
From Pilot to Profit: How Pharma Leaders Are Scaling AI Across the Drug Lifecycle
Author(s)Mohd Haque
Most pharma companies have promising AI pilots. Few have built the conditions to scale them. Here's what separates the leaders from the rest.
Advertisement
Advertisement
Pharma companies have spent the last several years testing AI across discovery, development, manufacturing, and commercialization. With the potential to create $60 billion to $110 billion annual economic value across the industry, AI has become too important to remain stuck in pilot mode. Today, only a small group of companies is starting to turn AI into measurable business gains, with Boston Consulting Group finding that AI-first biopharma companies are reporting 5 percent to 15 percent revenue uplift.
Related to this article
PaxSafe's Mark Talens on why pharma supply chain AI fails before it starts — and the data foundry framework that changes that.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
Advertisement
Advertisement